Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival

被引:0
|
作者
Theresa M Thole
Marco Lodrini
Johannes Fabian
Jasmin Wuenschel
Sebastian Pfeil
Thomas Hielscher
Annette Kopp-Schneider
Ulrike Heinicke
Simone Fulda
Olaf Witt
Angelika Eggert
Matthias Fischer
Hedwig E Deubzer
机构
[1] Oncology and SCT,Department of Pediatric Hematology
[2] Charité–Universitätsmedizin Berlin,Department of Pediatric Hematology and Oncology
[3] Campus Virchow-Klinikum,Department of Biostatistics
[4] University of Heidelberg,Department of Pediatric Hematology and Oncology
[5] Clinical Cooperation Unit Pediatric Oncology,Department of Children and Adolescent Medicine
[6] German Cancer Research Center (DKFZ) and German Consortium for Translational Cancer Research (DKTK),undefined
[7] German Cancer Research Center (DKFZ),undefined
[8] Institute for Experimental Cancer Research in Pediatrics,undefined
[9] J. W. Goethe University Hospital Frankfurt,undefined
[10] German Cancer Consortium (DKTK),undefined
[11] German Cancer Research Center (DKFZ),undefined
[12] University of Cologne,undefined
[13] Center for Molecular Medicine Cologne,undefined
[14] University of Cologne,undefined
[15] Junior Neuroblastoma Research Group,undefined
[16] Experimental and Clinical Research Center (ECRC) of the Max-Delbrück Center for Molecular Medicine (MDC) in the Helmholtz Community and the Charité–University Medicine Berlin,undefined
[17] 11Current address: Phenex Pharmaceuticals AG,undefined
[18] Waldhofer Straße 104,undefined
[19] Heidelberg 69123,undefined
[20] Germany.,undefined
来源
Cell Death & Disease | 2017年 / 8卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The number of long-term survivors of high-risk neuroblastoma remains discouraging, with 10-year survival as low as 20%, despite decades of considerable international efforts to improve outcome. Major obstacles remain and include managing resistance to induction therapy, which causes tumor progression and early death in high-risk patients, and managing chemotherapy-resistant relapses, which can occur years after the initial diagnosis. Identifying and validating novel therapeutic targets is essential to improve treatment. Delineating and deciphering specific functions of single histone deacetylases in neuroblastoma may support development of targeted acetylome-modifying therapeutics for patients with molecularly defined high-risk neuroblastoma profiles. We show here that HDAC11 depletion in MYCN-driven neuroblastoma cell lines strongly induces cell death, mostly mediated by apoptotic programs. Genes necessary for mitotic cell cycle progression and cell division were most prominently enriched in at least two of three time points in whole-genome expression data combined from two cell systems, and all nine genes in these functional categories were strongly repressed, including CENPA, KIF14, KIF23 and RACGAP1. Enforced expression of one selected candidate, RACGAP1, partially rescued the induction of apoptosis caused by HDAC11 depletion. High-level expression of all nine genes in primary neuroblastomas significantly correlated with unfavorable overall and event-free survival in patients, suggesting a role in mediating the more aggressive biological and clinical phenotype of these tumors. Our study identified a group of cell cycle-promoting genes regulated by HDAC11, being both predictors of unfavorable patient outcome and essential for tumor cell viability. The data indicate a significant role of HDAC11 for mitotic cell cycle progression and survival of MYCN-amplified neuroblastoma cells, and suggests that HDAC11 could be a valuable drug target.
引用
收藏
页码:e2635 / e2635
相关论文
共 50 条
  • [21] HDAC5 is required for maintenance of pericentric heterochromatin, and controls cell-cycle progression and survival of human cancer cells
    P Peixoto
    V Castronovo
    N Matheus
    C Polese
    O Peulen
    A Gonzalez
    M Boxus
    E Verdin
    M Thiry
    F Dequiedt
    D Mottet
    Cell Death & Differentiation, 2012, 19 : 1239 - 1252
  • [22] HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro
    Vallo, Stefan
    Xi, Wang
    Hudak, Lukasz
    Juengel, Eva
    Tsaur, Igor
    Wiesner, Christoph
    Haferkamp, Axel
    Blaheta, Roman A.
    ANTI-CANCER DRUGS, 2011, 22 (10) : 1002 - 1009
  • [23] HDAC11 function as a transcriptional regulator in immature myeloid cells to myeloid-derived suppressor cells transition
    Chen, Jie
    Cheng, Fengdong
    Sahakian, Eva
    Powers, John
    Wang, Zi
    Villagra, Alejandro
    Pinilla-Ibarz, Javier
    Sotomayor, Eduardo M.
    CANCER RESEARCH, 2018, 78 (13)
  • [24] HDAC11 is related to breast cancer prognosis and inhibits invasion and proliferation of breast cancer cells
    Zhao, Hao
    Zhang, Xu-Ming
    Xiao, Sheng
    Wu, Zhen-Ru
    Shi, Yu-Jun
    Xie, Ming-Jun
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2023, 16 (07): : 172 - 183
  • [25] Loss of HDAC11 Promotes Myeloid-Derived Suppressor Cells Inhibition of T Cell Function in a Murine Lymphoma Microenvironment
    Chen, Jie
    Cheng, Fengdong
    Wang, Michael
    Sahakian, Eva
    Powers, John J.
    Ibarz, Javier Pinilla
    Smith, Mitchell R.
    Sotomayor, Eduardo
    BLOOD, 2018, 132
  • [26] Staphylococcus aureus induces mitophagy via the HDAC11/IL10 pathway to sustain intracellular survival
    Yang, Yaji
    Zhou, Haotian
    Li, Feilong
    Zhang, Yanhao
    Yang, Jianye
    Shen, Yidong
    Hu, Ning
    Zou, Quanming
    Qin, Leilei
    Zeng, Hao
    Huang, Wei
    JOURNAL OF TRANSLATIONAL MEDICINE, 2025, 23 (01)
  • [27] Mitotic phosphorylation of Tau/MAPT modulates cell cycle progression in prostate cancer cells
    Clementi, Letizia
    Sabetta, Samantha
    Zelli, Veronica
    Compagnoni, Chiara
    Tessitore, Alessandra
    Mattei, Vincenzo
    Angelucci, Adriano
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (10) : 7689 - 7701
  • [28] Hydrogen peroxide inhibits cell cycle progression by inhibition of the spreading of mitotic CHO cells
    Muñoz, CM
    van Meeteren, LA
    Post, JA
    Verkleij, AJ
    Verrips, CT
    Boonstra, J
    FREE RADICAL BIOLOGY AND MEDICINE, 2002, 33 (08) : 1061 - 1072
  • [29] Mitotic phosphorylation of Tau/MAPT modulates cell cycle progression in prostate cancer cells
    Letizia Clementi
    Samantha Sabetta
    Veronica Zelli
    Chiara Compagnoni
    Alessandra Tessitore
    Vincenzo Mattei
    Adriano Angelucci
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 7689 - 7701
  • [30] A Novel Hole of Histone Deacetylase 11 (HDAC11) in Regulation of Myeloid-Derived Suppressor Cell (MDSC) Expansion
    Sahakian, Eva
    Powers, John
    Rock-Klotz, Jennifer
    Adriani, Marsilio
    Woan, Karrune V.
    Merino, Oscar
    Gill, Ajaypal S.
    Deng, Susan
    Cheng, Fengdong
    Villagra, Alejandro
    Luetteke, Noreen
    Seto, Edward
    Sotomayor, Eduardo M.
    Borrello, Ivan M.
    Pinilla-Ibarz, Javier
    BLOOD, 2011, 118 (21) : 1048 - 1048